In EAE (experimental autoimmune encephalomyelitis), agonists of PPARs (peroxisome proliferator-activated receptors) provide clinical benefit and reduce damage. In contrast with PPARc, agonists of PPARd are more effective when given at later stages of EAE and increase myelin gene expression, suggesting effects on OL (oligodendrocyte) maturation. In the present study we examined effects of the PPARd agonist GW0742 on OPCs (OL progenitor cells), and tested whether the effects involve modulation of BMPs (bone morphogenetic proteins). We show that effects of GW0742 are mediated through PPARd since no amelioration of EAE clinical scores was observed in PPARd-null mice. In OPCs derived from E13 mice (where E is embryonic day), GW0742, but not the PPARc agonist pioglitazone, increased the number of myelin-producing OLs. This was due to activation of PPARd since process formation was reduced in PPARd-null compared with wild-type OPCs. In both OPCs and enriched astrocyte cultures, GW0742 increased noggin protein expression; however, noggin mRNA was only increased in astrocytes. In contrast, GW0742 reduced BMP2 and BMP4 mRNA levels in OPCs, with lesser effects in astrocytes. These findings demonstrate that PPARd plays a role in OPC maturation, mediated, in part, by regulation of BMP and BMP antagonists.
INTRODUCTION
Studies from our laboratory (Feinstein et al., 2002) and others (Diab et al., 2002; Natarajan and Bright, 2002) have shown that agonists of PPARc (peroxisome proliferator-activated receptor c) reduce clinical and histological symptoms in EAE (experimental autoimmune encephalomyelitis), an animal model of MS (multiple sclerosis). These effects are due, in part, to suppression of inflammatory gene expression Xu et al., 2007) , inhibition of activated T-cell proliferation and production of inflammatory mediators (Feinstein, 2003; Kielian and Drew, 2003) , and reduction of leucocyte infiltration into the CNS (central nervous system) (Klotz et al., 2007) . These findings have led to the design of small clinical trials in relapsing remitting MS patients (Miller et al., 2005; Kaiser et al., 2009 ) with encouraging results. Similarly, agonists of PPARa show anti-inflammatory actions on glial cells (Deplanque et al., 2003; Xu et al., 2005 Xu et al., , 2006 and benefit in EAE (Lovett-Racke et al., 2004; Dasgupta et al., 2007; Xu et al., 2007) .
In contrast with PPARa and PPARc, studies of the PPARd (also referred to as PPARb or PPARb/d) isoform in EAE are limited. PPARd is expressed throughout the body in most tissues and is the most abundant PPAR in brain (Michalik et al., 2003) . The knowledge that activation of PPARd regulates lipid metabolism (Basu-Modak et al., 1999; Kliewer et al., 2001; Rosenberger et al., 2002) , raised the possibility that PPARs might regulate lipid metabolism in OLs (oligodendrocytes). Studies from the Skoff laboratory (Granneman et al., 1998) have shown that PPARd is the major PPAR isotype expressed in optic and sciatic nerve, and is mainly expressed in the OL population. A subsequent study (Saluja et al., 2001) confirmed that PPARd, but not PPARc, selective agonists increased OL differentiation, including increasing MBP (myelin basic protein) and PLP (proteolipid protein) protein and mRNA levels.
Based on the above findings, we previously tested whether PPARd agonists could provide protection in EAE (Polak et al., 2005) . We found that, in contrast with PPARa and PPARc agonists, treatment with a PPARd agonist did not significantly reduce disease severity during the early stages of EAE, but instead showed benefit when given at the peak of disease. This was accompanied by reductions in the appearance of cortical lesions, neuronal damage and glial inflammation. Moreover, in contrast with PPARc agonists, the selective PPARd agonist GW0742 did not suppress proinflammatory cytokine production from T-cells, which may account for its reduced efficacy to influence early stages of EAE. GW0742 also caused an increase in myelin gene expression in EAE brains, suggesting a distinct mechanism of action possibly involving effects on OL maturation or survival.
Among the many factors implicated in OPC (OL progenitor cell) maturation are members of the BMP (bone morphogenetic protein) family. BMPs were originally identified as extracellular factors able to induce bone formation, but were later shown to be expressed in other tissues and play a role in development of other organs, including the nervous system (Goumans and Mummery, 2000; ten Dijke et al., 2003) . BMPs belong to the TGF (transforming growth factor) superfamily which, upon binding to their cognate receptors, activate phosphorylation of Smad proteins, which in turn bind to specific promoter elements and regulate gene transcription. A key gene target of BMP signalling are Id (inhibitors of differentiation) proteins similar in structure to bHLH (basic helix-loop-helix) transcription factors, but lacking the DNAbinding domain (Miyazono and Miyazawa, 2002) . Id proteins can therefore form heterodimers with other bHLH proteins, but the resulting complex is inactive. Both BMPs and their cognate receptors have been shown to be expressed by OLs during normal development (Cheng et al., 2007; See and Grinspan, 2009) .
BMP signalling is regulated by interactions with a class of molecules referred to collectively as BMP antagonists (Yanagita, 2005) which function primarily by direct association with BMPs, thereby preventing binding to BMP receptors. BMP signalling has been shown to play a role in OL maturation and survival, since treatment with BMP antagonists promotes OL maturation (Mehler et al., 1997; Mabie et al., 1999; Mehler et al., 2000; Mekki-Dauriac et al., 2002) , and the BMP antagonist noggin induced oligodendrogenesis in human embryonic stem cells (Izrael et al., 2007) . The ability of BMPs to reduce OL maturation is due in large part to formation of complexes between Id proteins and the bHLH proteins Olig1 (OL transcription factor 1) and Olig2 which have been well characterized for their involvement in OL maturation (Cheng et al., 2007; Bilican et al., 2008) . Given the importance of this signalling system in OL maturation, and in view of the fact that GW0742 increased myelin expression, we hypothesized that the effects of PPARd agonists could involve modulation of the BMP signalling system.
In the present study we have used PPARd-null mice to show that the beneficial effects of GW0742 in EAE are dependent upon the presence of functional PPARd, and that PPARd plays a role in regulating the normal processes of OL maturation. We also demonstrate that the effects of PPARd involve regulation of BMP and BMP antagonist expression in OPCs and astrocytes. Taken together these findings support the concept that PPARd plays an important role in the normal maturation of OPCs, and suggest that PPARd agonists provide benefit in EAE by accelerating OPC maturation.
MATERIAL AND METHODS

Animals
Female C57BL/6 mice, aged 6-8 weeks, were from Charles River Breeding. PPARd-null mice were generated as previously described (Peters et al., 2000) . Pregnant SpragueDawley rats were purchased from Charles River Breeding, and used to provide P1 (where P is post-natal day) pups. Mice were maintained in a controlled 12 h:12 h light/dark environment and provided food ad libitum. All experiments were approved by the local IACUC (Institutional Animal Care and Use Committee).
Cell culture
Enriched cultures of primary mouse or rat astrocytes were prepared from P1 pups using procedures described previously, including complete change of media [DMEM (Dulbecco's modified Eagle's medium) containing 10% fetal calf serum and antibiotics] every 3 days (Dello Russo et al., 2003) . The cells reached confluency after 7-8 days. At that time the cells were shaken for 2 h to remove adhering microglia, and overnight at 225 rev./min at 37˚C to dislodge OPCs. The remaining cells are approximately 95% astrocytes by staining for the astrocyte-specific protein GFAP (glial fibrillary acidic protein), and 5% adherent microglia.
OPCs were prepared from E13 (where E is embryonic day) mouse pups using a recently described method (Pedraza et al., 2008) . In brief, E13 embryos were removed, and then washed in cold PBS; the cerebellum was removed and meninges dissected away. The tissue from six to eight brains was triturated by 40 passages through a 1 ml pipette tip in DMEM/F12 and B27 neuronal supplement, and then filtered through a 70 mm-poresize cell strainer. The cells were plated at the equivalent of two brains per T25 flask in 8 ml of NPM (neural proliferation medium) containing DMEM/F12/B27 neuronal supplement and 10 ng/ml EGF (epidermal growth factor; Sigma). The cells were passaged every 3 days by trituration and plated at a 1:5 ratio in NPM. After two passages, the cells were mechanically dissociated with a 1 ml pipette, then plated on to PDL (poly-D-lysine)-coated coverslips in NPM supplemented with 10 ng/ml bFGF (basic fibroblast growth factor) and 10 ng/ml PDGFa (platelet-derived growth factor a) [this is ODM (OL differentiation medium)].
For the data shown in Figure 2 , cells were grown for 48 h on PDL-coated coverslips in ODM, the medium was then changed, and cells grown for a further 5 days in SatoBottenstein media in the absence of bFGF/PDGF, but containing 30 nM T3 and 10 mM AraC to reduce astrocyte proliferation, and either 10 mM of the PPARc agonist pioglitazone, 10 mM of the PPARd agonist GW0742, or the equivalent amount of DMSO vehicle to determine whether these drugs would induce further OPC maturation.
Induction of EAE
EAE was actively induced in 6-8-week-old mice using synthetic MOG (myelin OL glycoprotein peptide 35-55) as described previously (Feinstein et al., 2002) . The MOG 35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) was purchased from Anaspec. Mice were injected subcutaneously (two 100 ml injections into adjacent areas in one hind limb) with an emulsion of 300 mg of MOG 35-55 dissolved in 100 ml of PBS, mixed with 100 ml of complete Freund's adjuvant containing 500 mg of Mycobacterium tuberculosis (Difco). Immediately after MOG injection, the animals received an i.p. (intraperitoneal) injection of 200 ng of PT (pertussis toxin; List Biochemicals) in 200 ml of PBS. At 2 days later, the mice received a second PT injection, and 1 week later they received a booster injection of MOG .
Clinical assessment of EAE
Clinical signs were scored on a 5 point scale: grade 0, no clinical signs; 1, limp tail; 2, impaired righting; 3, paresis of one hind limb; 4, paresis of two hind limbs; 5, death. Scoring was performed at the same time each day by a blinded investigator.
Treatment of mice with PPARd agonist
The selective PPARd agonist GW0742 {4-[2-(3-fluoro-4-trifluoromethylphenyl)-4-methylthiazol-5-ylmethylsulfanyl]-2-methylphenoxy)-acetic acid} was synthesized at GlaxoSmithKline as described previously (Sznaidman et al., 2003) and was provided by Dr Tim Willson (GlaxoSmithKline, Raleigh, NC, U.S.A.). Chow containing 100 p.p.m. GW0742 was prepared by Research Diets by mixing 100 mg of drug with 1 kg of Purina mouse chow 5001. Mice were provided free access to chow, and on average consumed 2 g per mouse per day, giving an average daily dose of 10 mg of GW0742/kg. This dose is similar to that previously use by our group and others for studies of other PPAR agonists in EAE models (Feinstein et al., 2002) .
mRNA analysis
Total RNA from cells and tissues was isolated using TRIzolH reagent (Invitrogen/Gibco); aliquots were converted into cDNA using random hexamer primers, and mRNA levels estimated by qPCR (quantitative PCR). PCR conditions were 35 cycles of denaturation at 94˚C for 10 s, annealing at 58-64˚C for 15 s and extension at 72˚C for 20 s on a Corbett Rotorgene realtime PCR unit. PCR was performed using Taq DNA polymerase (Invitrogen), and contained SYBR Green (SybrGreen1 100006 concentrate, diluted 1:10000; Molecular Probes). Relative mRNA concentrations were calculated from takeoff point of reactions using the software provided by the manufacturer, and normalized to a-tubulin and GDH (glyceraldehyde-3-phosphate dehydrogenase) measured in the same samples. Melting curve analysis and agarose gel electrophoresis ensured production of single and correct sized products. Primers were derived from published sequence information using Perl Primer software (perlprimer.sourceforge.net) to generate PCR products ranging from 100 to 250 bp. The primers used were: GDH forward, 59-GCCAAGTATGATGACATCAAGAAG-39; GDH reverse, 59-TCCAGGGGTTTCTTACTCCTTGGA-39; Olig1 forward, 59-ATG-CCATCGGTGTTCGGACTTACT-39; Olig1 reverse, 59-TGTGGTTAA-GGACCAGCCTGTGAA-39; GalC (galactosyl ceramidase) forward, 59-AGGACATGCGGACGTTACAGCTAA-39; GalC reverse, 59-TCCATAGGATCGTGCCGTTCAACA-39; CGT (galactose ceramide galactosyl transferase) forward, 59-ACATTTGCAGTTCTCC-TTGCTGCC-39; CGT reverse, 59-AAGGCTACTGAGTTGGGCTGA-TGT-39; PDGFR-a forward, 59-ACCTTGCACAATAACGGGAG-39; PDGFR-a reverse, 59-GAAGCCTTTCTCGTGGACAG-39; PPARd forward, 59-GCCCAAGTTCGAGTTTGCTGTCAA-39; PPARd reverse, 59-TTAGCCACTGCATCATCTGGG-39; UCP3 (uncoupling protein 3) forward, 59-GAGAGGAAATACAGAGGGAC-39; UCP3 reverse, 59-GGGAGGTTGTCAGTAAACAG-39; ANGPTL-4 (angiopoietinlike 4) forward, 59-GCCACCCACTTACACAGGCCG-39; ANGPTL-4 reverse, 59-CCAGGCCCAGCCAGAACTCG-39; Noggin forward, 59-TGAGCAAGAAGCTGAGGAGGAAGT-39; Noggin reverse, 59-AGGTGCACAGACTTGGATGGCTTA-39; Gremlin forward, 59-AC-AGAGCGCAAGTATCTGAAGCGA-39; Gremlin reverse, 59-AGGA-GTTGCACTGGCCATAACAGA-39; Follistatin forward, 59-TGGA-TCTTGCAACTCCATCTCGGA-39; Follistatin reverse, 59-TGC-CCAAAGGCTATGTCAACACTG-39; Bambi forward, 59-TTCT-GTGTTTGCCTGGCCTGTTTC-39; Bambi reverse, 59-AGCAAGCTG-TGGAGAGGTCAAGAR-39; BMP2 forward, 59-TGATCACCTG-AACTCCACCAACCA-39; BMP2 reverse, 59-AACCCTCC-ACAACCATGTCCTGAT-39; BMP4 forward, 59-AGAACTGCCG-TCGCCATTCACTAT-39; and BMP4 reverse, 59-AGTTGAGGTGA-TCAGCCAGTGGAA-39.
Immunocytochemical staining
E13 OPCs were grown on PDL-coated coverslips, treated and prepared for staining. Coverslips were then rinsed in PBS, fixed with 4% PFA (paraformaldehyde) for 10 min, rinsed in PBS, incubated with mouse anti-MBP (1:200; Chemicon), goat anti-noggin (1:40; R&D Systems), rabbit anti-PLP (1:300; Santa Cruz Biotechnology), rabbit anti-GFAP (1:500; Dako) or rabbit anti-PDGFRa (1:300; Santa Cruz Biotechnology) diluted in 1% donkey serum/PBS, overnight at 4˚C. Cells were rinsed in PBS, incubated with anti-rabbit-TRITC (tetramethylrhodamine b-isothiocyanate, 1:200; Southern Biotechnology) and anti-mouse-FITC (1:200; Sigma) for 2 h at 37˚C, rinsed in PBS, incubated with DAPI (at 1:500) in PBS for 10 min, rinsed in PBS, and then mounted on coverslips.
Data analysis
Quantification of the cell numbers in Figure 2 was performed manually, and in Figures 4 and 6 performed using Zeiss Axiovision version 4.5. Comparisons between groups were made using a Student's unpaired t test. Comparisons of the number of stained cells in Figure 2 was done using x 2 analysis. Comparison of clinical signs in WT (wild-type) compared with PPARd-null mice was performed by two-way repeated measures ANOVA using data from day 25 (the start of treatment) to the end of the study (day 49). Values are means¡S.E.M., and for all comparisons significance was taken at P,0.05.
RESULTS
PPARd mediates protective effects of GW0742
We have previously shown that treatment of C57BL/6 mice with the PPARd agonist GW0742 ameliorated clinical and histological signs of EAE when administered to mice with moderate disease severity (Polak et al., 2005) . To confirm that these effects were mediated via activation of PPARd, and not by off-target actions of the agonist, we tested whether GW0742 influenced the course of disease in PPARd-null mice in which endogenous PPARd is inactivated in all cells and tissues by insertion of the neomycin gene into the DNAbinding domain. As previously observed, providing GW0742 to WT mice at 25 days after immunization (at which time they show moderate clinical signs) significantly reduced clinical signs beginning approx. 15 days later ( Figure 1A) . Immunization of PPARd-null mice with MOG peptide resulted in a similar disease incidence and severity as WT mice, suggesting that PPARd does not play a significant role in the early stages of EAE. However, in contrast with the WT mice, treatment with GW0742 did not effect disease progression for up to 25 days of treatment ( Figure 1B ). This provides strong evidence that the effects of GW0742 are mediated through this receptor and are not due to off-target actions. Since the receptor is inactivated in all cells throughout the body, these results do not allow us to conclude whether the loss of GW0742 benefit is due to lack of PPARd from brain, or from some other tissue; however, our previous studies did not reveal any effect of GW0742 on splenic T-cells, suggesting that lack of PPARd from brain may account for the current findings.
Effects of GW0742 on OPC maturation
We hypothesized that GW0742 could provide benefit in EAE involving effects on OL maturation or survival. To address this, we first tested whether GW0742 influenced maturation of OPCs generated from E13 mice. These preparations are grown as neurospheres, then grown on PDL-coated plates in medium containing bFGF and PDGF which leads to differentiation (Pedraza et al., 2008) . After 7 days growth on PDLcoated slides, OPCs show little staining for MBP ( Figure 2A ) and the presence of numerous GFAP + -stained cells. After 5 days growth in GW0742, the number of GFAP-stained cells was significantly increased from 13% (in vehicle-treated cultures) to 26% (P,0.0001, as measured using a x 2 test); and their morphology more closely resembled that of mature astrocytes. In these cultures we also observed an increased number of cells stained for MBP, which increased from none in vehicle-treated cultures to 4% in the treated cultures (P,0.0001, as measured using a x 2 test), as well as the appearance of myelin sheaths and longer processes ( Figure 2B ). Treatment with the PPARc agonist pioglitazone did not significantly increase the number of GFAP + -stained cells (16% of all cells, P.0.05 compared with vehicle), although they again showed a more mature phenotype; very few cells (0.5% of all cells, P50.07) showed positive staining for MBP ( Figure 2C) .
To look at the initial events involved in the effects of GW0742 on OPC maturation, we measured mRNA levels of known markers of OPC maturation (Figure 3 ). After treatment of E13 OPCs with 3 mM GW0742 for 24 h, there was a significant increase in expression of Olig1, CGT, PDGFRa and an increase in GalC compared with vehicle-treated cells ( Figures 3A-3D) . However, at this timepoint there was no change in PLP mRNA levels ( Figure 3E ). Levels of PPARd were also significantly increased by GW0742 (Figure 3F ), as were levels of the well-characterized PPARd target gene ANGPTL-4, although interestingly, not of a second target gene UCP3 (Figures 3G and 3H) .
Staining for the early OPC marker PDGFRa confirmed that treatment with GW0742 for 24 h increased OPC maturation as indicated by an increase in cell migration (Figure 4 ). GW0742 did not modify the total number of spheres present; however, the average size of the spheres was significantly reduced (diameter of 40.7¡2.1 mm compared with 30.4¡1.6 mm, P,0.0005) (Figures 4A and 4B) . At the same time, the total number of cells that migrated out from the spheres was significantly increased by GW0742 (814¡38 compared with 1135¡105 cells per field; DMSO compared with GW0742, P,0.05) ( Figures 4C and 4D) , and those cells showed a greater number of processes ( Figures 4E and 4F ).
PPARd mediates OPC maturation
To determine whether endogenous PPARd plays a role in normal OL maturation, we prepared primary OPCs from E13 WT and PPARd-null mice and examined process formation under full differentiation conditions (e.g. medium containing PDGFa, bFGF and B27 supplement). After 7 days, WT cells had more primary processes than did PPARd-null cells ( Figure 5A ), and quantification of process number ( Figure 5B ) revealed that PPARd-null cells had significantly fewer processes per cell (2.3¡0.04) than WT cells (3.1¡0.1). Analysis of process distribution ( Figure 5C ) showed a left shift in the average number of processes per cell in PPARd-null cells, suggesting that process maturation was not completely inhibited, but either temporally delayed or limited to fewer processes in the null cells.
GW0742 increases noggin expression
In view of reports that BMPs inhibit OL maturation (Gross et al., 1996; Hardy and Friedrich, 1996; Zhu et al., 1999; Mehler et al., 2000; Mekki-Dauriac et al., 2002; Gomes et al., 2003) , we hypothesized that GW0742 might act by increasing BMP antagonist expression. Immunostaining of E13 OPCs treated for 24 h with GW0742 showed staining for the BMP antagonist noggin, primarily in the non-migrating cells which remained within spheres ( Figures 6A and 6B ). Quantification of cell numbers revealed no significant effect of treatment on Effect of GW0742 on OPC maturation Mouse E13 OPCs were plated on to PDL-coated coverslips, grown for 48 h in differentiation medium, medium replaced with SatoBottenstein medium, and cells grown for a further 5 days in the absence of growth factors and in the presence of (A) vehicle, (B) 10 mM GW0742 or (C) 10 mM pioglitazone. Cells were fixed and stained for GFAP (TRITC, red), MBP (FITC, green) and nuclei [DAPI (49,6-diamidino-2-phenylindole), blue]. Images shown are representative fields of view from three or four slides examined per condition.
There was a significant increase in the number of GFAP + cells from 130/993 (13.0%) in vehicle-treated, to 140/643 (25.5%) in GW0742-treated cultures (P,0.0001, as measured using a x 2 test), but not in the pioglitazone-treated cultures (119/742; 16.1%). The number of MBP + cells was significantly increased from none in the vehicle-treated to 20/643 (4.0%) in the GW0742-treated cells (P,0.0001), but not in the pioglitazone-treated cultures (4/742; 0.5%).
PPARd increases OPC maturation
E 2010 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited. the total number of spheres (20.4¡3 compared with 28.0¡5, average number of spheres per field, DMSO compared with GW0742, P.0.05). However, the number of noggin-stained spheres was significantly increased (from 7.4¡2 to 21.4¡4 per field, P,0.01). This increased number of noggin-stained spheres reflects a significant increase from 40¡10% to 79¡6% (P,0.01) of all spheres. We did not observe any significant co-localization of noggin with either PDGFRa (Figures 7A and 7B) , PLP ( Figures 7C and 7D) or GFAP ( Figures 7E and 7F ), suggesting that expression was restricted to immature progenitor cells. Analysis by qPCR showed that, after 24 h of treatment, GW0742 did not increase noggin mRNA levels, although we did observe a significant decrease in both BMP2 and BMP4 mRNA levels ( Figure 8A ).
Since there are some astrocytes present in the OPC cultures, we tested whether GW0742 influenced BMP or BMP antagonist expression in enriched astrocyte cultures. After 24 h we observed a significant increase of noggin mRNA levels in astrocytes ( Figure 8B) ; interestingly, this increase appeared to be selective for noggin since mRNA levels of other BMP antagonists (gremlin, follistatin and bambi) were not increased (in fact gremlin mRNA levels were significantly reduced). In contrast with OPCs, GW0742 did not increase PPARd mRNA levels ( Figure 9A ). Interestingly, GW0742 caused a significant increase in the PPARd target gene UCP3, but not in ANGPTL-4. Consistent with the increase in noggin mRNA, we observed a large increase in noggin staining, present in vesicular structures around the nucleus of primary astrocytes treated with 3 mM GW0742 for 24 h (Figure 10 ).
DISCUSSION
In the present study we show that PPARd is involved in the regulation of OPC maturation and is associated with changes in the expression of BMPs and BMP antagonists. We previously have shown that treatment of EAE-immunized mice with GW0742 did not offer significant protection when administered early during disease evolution, but instead reduced clinical signs when given to mice showing moderate clinical signs (Polak et al., 2005) . In those studies, GW0742 did not suppress the ability of T-cells to produce IFNc (interferon c), providing a possible explanation for its inability to reduce early-stage EAE. In contrast, GW0742 significantly increased PLP and MBP mRNA levels in EAE mice, suggesting possible effects on OL maturation, survival or proliferation. The findings of the present study support this possibility since, in E13 OPCs, GW0742 induced maturation as determined by increased myelin gene expression, increased myelin sheets and increased numbers of pre-myelinating OPCs. The finding that mRNA levels for PLP were not increased suggests that GW0742 affects earlier stages of OPC maturation, although whether PLP is increased at later times is not yet known. Overall, these findings are in agreement with earlier results showing that the weaker PPARd agonist bromopalmitate (Granneman et al., 1998) and the more selective agonist L-796449 (Saluja et al., 2001 ) induced myelin expression in post-natal mouse OPC cultures. Furthermore, the results that GW0742 was ineffective at reducing clinical signs in PPARd-null mice confirms that the actions of this drug depend upon PPARd and are not due to off-target effects as has been reported for other PPAR agonists (Dello Russo et al., 2003) . We examined the specificity of PPAR agonist effects by comparing the actions of GW0742 with those of the selective PPARc agonist pioglitazone on OPC maturation (Figure 2 ). Increased MBP staining was seen primarily in the GW0742-treated OPCs, suggesting a more important role for PPARd as compared with PPARc in the OPC maturation process. Interestingly, treatment with either GW0742 or pioglitazone led to more mature astrocyte morphology in the GFAPpositive-stained cells, suggesting that both PPARs may be involved in astrocyte maturation. Our findings also show that endogenous PPARd plays a role in OPC maturation, since in PPARd-deficient OPCs the distribution and average number of processes was significantly reduced compared with WT OPCs. It should be noted that, despite the absence of PPARd, these OPCs still developed processes and sheaths, but OPC maturation was reduced, pointing to PPARd as a modulator of the maturation process. PPARd may be considered as a potential feed-forward factor along OPC maturation, even though it is not yet clear at which step through the maturation PPARd exerts its role. We focused attention on the class of BMPs and BMP antagonists for several reasons. Numerous studies have shown a role for BMPs in regulating neural stem cell commitment (Kondo and Raff, 2004; Gaughwin et al., 2006; Hampton et al., 2007a; Talbott et al., 2006; Cheng et al., 2007) ; and in restricting OPC maturation during normal development (Gross et al., 1996; Hardy and Friedrich, 1996; Zhu et al., 1999; Mehler et al., 2000; Mekki-Dauriac et al., 2002; Gomes et al., 2003) . This has been thought to be a BMP-dependent induction of Id proteins that can bind to and inactivate the bHLH proteins Olig1 and Olig2 (Samanta and Kessler, 2004) which promote OPC maturation.
Recently, it was shown that in EAE, BMP4, -6 and -7 are up-regulated in lumbar spinal cord; with BMP4 being the most abundant mRNA detected, and being detected in astrocytes as well as in oligodendrocytes and macrophages (Ara et al., 2008) . In a second related study, it was found that BMP4 and BMP7 were increased following lysolecithininduced demyelination, and interestingly that phosphorylated Smad 1/5/8 was detected in astrocytes (Fuller et al., 2007) , suggesting that BMPs can induce astrogliosis and inhibit remyelination. Taken together, these findings raised the possibility that treatments or interventions that increase BMP GW0742 increases noggin expression in OPC cultures Mouse E13 OPCs were grown for 5 days in differentiation medium, then treated with (A) vehicle or (B) 3 mM GW0742 for 24 h. Cells were then fixed and immunostained for noggin. Cell counting was carried out to quantify the total number of spheres and total number of spheres stained for noggin in seven fields of view for each condition taken at 206magnification. There was a similar number of spheres in the two groups (20.4¡3 compared with 28.0¡5, average number of spheres per field, DMSO compared with GW0742, P.0.05). GW0742 significantly increased the number of noggin-stained spheres (from 7.4¡2 to 21.4¡4 per field, P,0.01) and the percentage of noggin-stained spheres increased from 40¡10% to 79¡6% (P,0.01). Representative images are shown for each condition.
antagonist expression, or reduce BMP expression, would facilitate OPC maturation. Several previous studies have shown that PPAR agonists can influence BMP signalling. In human umbilical vein endothelial cells, pioglitazone suppressed BMP2 expression (Zhang et al., 2008) , several PPARc agonists decreased BMP2 expression in human osteoblasts (Lin et al., 2007) , and in mouse gonadotopinoma cells, pioglitazone reduced BMP signalling including activation of Id1 expression and DNA synthesis (Takeda et al., 2007) . In the present study we extend this list by demonstrating that a PPARd agonist can decrease BMP2 and BMP4 expression in OPCs, and to our knowledge this is the first demonstration of any PPAR agonist increasing a BMP antagonist. Our results point to distinct effects of GW0742 on BMPs and their antagonists' in astrocytes and OPCs. In OPCs GW0742 primarily affected expression of BMP2 and BMP4 mRNAs with lesser effects on the BMP antagonists; in astrocytes the PPARd agonist had greater effects on expression of the BMP antagonists noggin and gremlin, with smaller effects on BMPs. The lack of significant changes in BMP2 and BMP4 expression in GW0742-treated astrocytes, together with down-regulation of the same BMPs in GW0742-treated OPCs, suggests the possibility of an autocrine short-range effect of BMPs in astrocytes and OPCs. This may be similar to the balance of interactions between BMPs and their antagonists that occur in the optic nerve which result in enhanced OPC maturation (Kondo and Raff, 2004) . This may guarantee cellular identity for astrocytes and precursor cell identity for OPCs. On the other hand, increase in noggin expression in astrocytes following GW0742 Figure 7 Noggin does not co-localize with OPC markers Mouse E13 OPCs were grown for 5 days in differentiation medium, then treated for 24 h with 3 mM GW0742 or vehicle. Cells were then fixed and immunostained for noggin (FITC, green) together with PDGFRa (A and B), PLP (C and D) or GFAP (E and F). Representative images are shown for each condition. Nog, noggin.
treatment could represent a modulatory mechanism of the intercellular communication between astrocyte and OPCs, and may suggest a PPARd-mediated role of astrocytes in OPC maturation.
At the protein level we observed in both OPCs and astrocytes that GW0742 treatment increased staining for noggin protein, although the increase was more robust in the primary astrocyte cultures. Whereas increased staining could be due to an overall increase in noggin expression, the fact that noggin is normally released raises the possibility that GW0742 reduced release from astrocytes. If so, the absence of strong intracellular noggin staining in the OPCs could be due to increased release owing to GW0742, suggesting cellspecific means of regulating release. The greater increase in primary astrocyte cultures compared with the astrocytes present in the OPC cultures could also be due to differences in the maturation state of astrocytes, suggesting that only more mature cells can highly express noggin.
Previous characterization of BMPs and BMP antagonists in astrocytes is limited. In optic nerve astrocytes, the mRNAs for gremlin, follistatin, chordin and bambi, but not noggin, were detected (Wordinger et al., 2002) ; and noggin mRNA was expressed in type 1 astrocytes in P6 rat optic nerve (Kondo and Raff, 2004) . Immunohistochemical staining demonstrated that noggin was primarily expressed in astrocytes in the dorsal spinal cord following rhizotomy, but was absent from non-injured spinal cords (Hampton et al., 2007b) . Mouse E13 OPCs (A) grown for 5 days in full medium and primary rat astrocytes (B) were treated with 3 mM GW0742 or vehicle for 24 h, and then RNA was isolated and qPCR used to measure relative mRNA levels of indicated genes. Values are means¡S.E.M. of the relative mRNA level normalized to values for GDH measured in the same samples, n53. The mRNA values for the vehicle groups were set to 1.0; *P,0.05, compared with the corresponding vehicle treated sample (as measured using an unpaired Student's t test). Figure 9 Regulation of PPARd target gene expression in astrocytes Primary rat astrocytes were treated with 3 mM GW0742 or vehicle (VEH) for 24 h then RNA isolated and qPCR used to measure relative mRNA levels of (A) PPARd and its target genes, (B) UCP3 and (C) ANGPTL-4. Values are means¡S.E.M. of the relative mRNA level normalized to values for GDH measured in the same samples, n53. The mRNA values for the vehicle groups were set to 1.0; *P,0.05, compared with the corresponding vehicle-treated sample (as measured using an unpaired Student's t test).
Figure 10
GW0742 increases noggin expression in astrocytes Primary rat astrocytes were treated for 24 h with 3 mM GW0742 or vehicle, after which cells were fixed and immunostained for noggin (Nog) and GFAP.
Astrocytes have been shown to express BMP4 in the adult rat CNS (Mikawa et al., 2006) , BMP4 and 7 primarily in olfactory bulb astrocytes throughout development (Peretto et al., 2002) , and the mRNAs for BMP2, 4, 5 and 7 in cultured adult optic head astrocytes (Wordinger et al., 2002) . It has also been shown that BMP2/4 is increased in ischaemic astrocytes (Xin et al., 2006) , and that the mRNA levels of BMP4, but not BMP2, are increased in astrocytes after spinal cord injury (Chen et al., 2005) , suggesting regulation following injury. These indications that BMP levels are increased under pathological conditions are consistent with our findings that a treatment to reduce pathology leads to a reduction in astroglial BMP levels.
The findings in the present study that agonists of PPARd can down-regulate the BMP signalling system may be of particular relevance during diseases such as EAE since inflammatory conditions have been shown to increase BMP signalling. For example, in prostate cancer cells, NF-kB (nuclear factor kB) binds to the BMP2 promoter and induces BMP2 expression, and in chondrocytes, TNFa (tumour necrosis factor a) induces BMP2 (Fukui et al., 2006) , most probably by also binding to the BMP2 promoter (Feng et al., 2003) . It is known that certain cytokines including TNFa and IFNc, which are present in the EAE brain, cause reversible inhibition of OPC proliferation and maturation (Agresti et al., 1996) , and that neurogenesis is sensitive to the inflammatory milieu and that chronic inflammation can reduce neurogenesis (Monje et al., 2003; Pluchino et al., 2008; Ekdahl et al., 2009; Whitney et al., 2009) . Therefore, in addition to direct effects on BMPs and BMP antagonists, it is likely that PPARd downregulates BMP signalling by attenuating inflammatory activation, as it has been shown to do in different cells and tissues (Delerive et al., 1999; Planavila et al., 2005; Kilgore and Billin, 2008; Smeets et al., 2008) .
In summary, the results of the present study confirm that PPARd mediates the effects of the synthetic agonist GW0742 in EAE and also plays a role in normal OPC maturation. Treatment with GW0742 regulates both BMP, as well as BMP antagonist, expression in astrocytes and OPCs, although with distinct effects. The molecular mechanisms underlying the ability of PPARd agonists to modulate BMP and BMP antagonist regulation could involve both direct effects on transcription via binding to PPAR-responsive elements, and indirect effects due to anti-inflammatory actions which could reduce inflammatory up-regulation of BMPs. The recent demonstration that PPARc agonists can be protective in relapsing/remitting MS patients (Kaiser et al., 2009) , together with the observations that PPARd agonists promote OPC maturation, suggests that clinical trials of pure or mixed PPAR agonists may be of therapeutic value in the treatment of MS.
